Last reviewed · How we verify

NCT07342712

Clinical Trail to Evaluate the Effect of Long-term Treatment With Gecacitinib on Myelofibrosis and Gene Mutation Levels

Active, enrolled Last updated 15 January 2026
What this trial tests

trial in Myelofibrosis in 40 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
1 August 2025
Primary endpoint
1 April 2026
7 December 2027

Quick facts

Lead sponsorFirst Affiliated Hospital of Zhejiang University
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment40
Start date1 August 2025
Primary completion1 April 2026
Estimated completion7 December 2027
Sites1 location across China

Conditions studied

Sponsor

First Affiliated Hospital of Zhejiang University

Who can join

Eligibility, any sex, with Myelofibrosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was an observational study, and about 40 patients with intermediate and high risk myelofibrosis who had participated in any previous clinical study of Gecacitinib hydrochloride and were still receiving Gecacitinib treatment in our center were expected to be enrolled. There was no additional drug intervention, only the myelofibrosis grade and gene mutation level of the patients were collected. Subjects who met all inclusion criteria and none of the exclusion criteria were eligible for inclusion in this study. After informed consent was obtained and screening was successful, bone marrow aspiration, bone marrow biopsy, and gene mutation testing were performed once. If bone marrow was extracted, peripheral blood could be used for gene mutation testing, and then annually until the permanent discontinuation of Gecacitinib.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Myelofibrosis

Currently open trials in the same condition.

Other First Affiliated Hospital of Zhejiang University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07342712.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing